STRATEC SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally.
Reasonable growth potential average dividend payer.
Share Price & News
How has Stratec's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: SBS exceeded the German Medical Equipment industry which returned 14.2% over the past year.
Return vs Market: SBS exceeded the German Market which returned 3% over the past year.
Share holder returns
Price Volatility Vs. Market
How volatile is Stratec's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Stratec undervalued based on future cash flows and its price relative to the stock market?
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Undervalued: SBS (€74.4) is trading below our estimate of fair value (€80.61)
Significantly Undervalued: SBS is trading below fair value, but not by a significant amount.
Price Based on Earnings
PE vs Industry: SBS is poor value based on its PE Ratio (64.5x) compared to the Medical Equipment industry average (34.9x).
PE vs Market: SBS is poor value based on its PE Ratio (64.5x) compared to the German market (19.7x).
Price Based on Expected Growth
Low PEG Ratio: SBS is poor value based on its PEG Ratio (2.3x)
Price Based on Value of Assets
PB vs Industry: SBS is good value based on its PB Ratio (6x) compared to the DE Medical Equipment industry average (6.1x).
How is Stratec expected to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Earnings vs Savings Rate: SBS's forecast earnings growth (28% per year) is above the savings rate (0.2%).
Earnings vs Market: SBS's earnings (28% per year) are forecast to grow faster than the German market (12.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SBS's revenue (9.9% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: SBS's revenue (9.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Estimates
Future Return on Equity
High Future ROE: SBS's Return on Equity is forecast to be low in 3 years time (17.3%).
How has Stratec performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: SBS's earnings have declined by -3.7% per year over the past 5 years.
Accelerating Growth: SBS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SBS had negative earnings growth (-39.6%) over the past year, making it difficult to compare to the Medical Equipment industry average (6.4%).
Return on Equity
High ROE: SBS's Return on Equity (9.3%) is considered low.
Return on Assets
ROA vs Industry: SBS's Return on Assets is below or equal to the Medical Equipment industry average last year.
Return on Capital Employed
ROCE Improving: SBS's Return on Capital Employed has declined over the past 3 years.
How is Stratec's financial position?
Financial Position Analysis
Short Term Liabilities: SBS's short term assets (€124.4M) exceeds its short term liabilities (€45.3M)
Long Term Liabilities: SBS's short term assets (€124.4M) exceeds its long term liabilities (€97.3M)
Debt to Equity History and Analysis
Debt Level: SBS's debt to equity ratio (50.6%) is considered high
Reducing Debt: SBS's debt to equity ratio has increased from 7.8% to 50.6% over the past 5 years.
Debt Coverage: SBS's debt is not well covered by operating cash flow (17.2%).
Interest Coverage: SBS's interest payments on its debt are well covered by EBIT (26.3x coverage).
Inventory Level: SBS has a high level of physical assets or inventory.
Debt Coverage by Assets: SBS's debt is covered by short term assets (assets are 1.655070x debt).
What is Stratec's current dividend yield, its reliability and sustainability?
Expected Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Dividend Yield and Payments Analysis
Notable Dividend: SBS's dividend (1.1%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.46%).
High Dividend: SBS's dividend (1.1%) is low compared to the top 25% of dividend payers in the German market (3.86%).
Stable Dividend: SBS's dividends per share have been stable in the past 10 years.
Growing Dividend: SBS's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (71.1%), SBS's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: SBS's dividends in 3 years are forecast to be well covered by earnings (33.5% payout ratio).
What is the CEO of Stratec's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Marcus Wolfinger (52yo)
Mr. Marcus Wolfinger has been Chairman of Management Board and Chief Executive Officer at STRATEC Biomedical AG since April 01, 2011 and its Member of the Management Board since July 1999. Mr. Wolfinger ha ...
CEO Compensation Analysis
Compensation vs. Market: Marcus's total compensation ($USD1.18M) is about average for companies of similar size in the German market ($USD1.16M).
Compensation vs Earnings: Marcus's compensation has been consistent with company performance over the past year.
Management Age and Tenure
Experienced Management: SBS's management team is seasoned and experienced (8.5 years average tenure).
Board Age and Tenure
Experienced Board: SBS's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Marcus Wolfinger (52yo)
Chairman of Board of Management & CEO
- Tenure: 8.5yrs
- Compensation: €1.06m
Robert Siegle (52yo)
Director of Finance & Human Resources and Member of Board of Management
- Tenure: 8.7yrs
- Compensation: €765.00k
Hermann Leistner (73yo)
Founder & Advisor
- Tenure: 8.6yrs
Director of Corporate Communications
- Tenure: 0yrs
Claus Vielsack (52yo)
Director of Product Development & Member of Board of Management
- Tenure: 5.7yrs
- Compensation: €669.00k
Head of Supply Chain Management & Senior VP
- Tenure: 0yrs
Head of Investor Relations
- Tenure: 0yrs
Frank Hiller (53yo)
Chairman of the Supervisory Board
- Tenure: 0.4yrs
Stefanie Remmele (41yo)
Member of Supervisory Board
- Tenure: 5.3yrs
- Compensation: €29.00k
Rainer Baule (71yo)
Deputy Chairman of Supervisory Board
- Tenure: 2.3yrs
- Compensation: €41.00k
Stratec SE's company bio, employee growth, exchange listings and data sources
- Name: Stratec SE
- Ticker: SBS
- Exchange: XTRA
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €893.641m
- Shares outstanding: 12.01m
- Website: https://www.stratec.com
Number of Employees
- Stratec SE
- Gewerbestrasse 35-37
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SBS||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Oct 1998|
|SBS||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Oct 1998|
|SBS||XTRA (XETRA Trading Platform)||Yes||Registered Shares||DE||EUR||Oct 1998|
|0RAR||LSE (London Stock Exchange)||Yes||Registered Shares||GB||EUR||Oct 1998|
|SBSD||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Registered Shares||GB||EUR||Oct 1998|
STRATEC SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates in three segments: ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/12 22:37|
|End of Day Share Price||2019/10/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.